evipedia.ai
← Back

sh-Polypeptide-4 for Hair Regrowth

Evidence Review created on 08/24/2026 using AI4L / Opus 5

Also known as: Recombinant Human Stem Cell Factor, rhSCF, Stem Cell Factor, SCF, KIT Ligand, KITLG, Mast Cell Growth Factor, Steel Factor, CG-SCF

Motivation

sh-Polypeptide-4 is a laboratory-made copy of a natural human signalling protein called stem cell factor. It is sold as an ingredient in scalp serums that promise thicker, fuller hair, usually alongside a handful of other laboratory-made growth proteins. Interest in it rests on a simple idea: the cells at the base of a hair follicle release signals that keep the follicle producing a thick, coloured hair, and adding one of those signals back might counter thinning.

The protein was first produced in the 1990s for a very different purpose, helping cancer patients rebuild blood cells, before laboratory work on scalp tissue linked it to hair colour and to the shrinking follicles of pattern hair loss. Cosmetic manufacturers began adding it to hair products in the decades that followed, and it now appears in serums priced far above the established treatments beside them on the shelf.

This review examines what is known about sh-Polypeptide-4 applied to the scalp: how it is thought to work, what has and has not been measured in people, what the safety record of the same protein in other settings shows, and how the evidence compares with that behind the alternatives.

Benefits - Risks - Protocol - Conclusion

This section lists high-level material that covers sh-Polypeptide-4 itself or the growth-factor signalling route through which it is claimed to act.

Fewer than five items are listed because no further source discusses sh-Polypeptide-4, or topical growth-factor signalling for hair, at the depth this section requires; the list is deliberately not padded with marginally relevant material.

Of the priority platforms, no directly relevant content was found on foundmyfitness.com (its hair material covers the established hair-loss drugs, ketoconazole, microneedling, greying and creatine, but not growth-factor signalling), chriskresser.com (nutrient-deficiency hair loss only), lifeextension.com (plant extracts and copper peptides, not recombinant growth factors) or lifespan.io (hair-follicle stem-cell biology, with no coverage of stem cell factor or growth-factor topicals).

Grokipedia

  • Stem cell factor

    Covers the protein sold as sh-Polypeptide-4 under its biological name, setting out its membrane-bound and soluble forms, its KIT signalling, and its roles in pigment cells and mast cells.

Examine

No Examine article exists for sh-Polypeptide-4 as of 08/24/2026. Examine covers dietary supplements and their ingredients; sh-Polypeptide-4 is a cosmetic ingredient applied to the skin, which falls outside that scope.

ConsumerLab

No ConsumerLab article exists for sh-Polypeptide-4 as of 08/24/2026. ConsumerLab tests ingestible supplements for identity and potency; a topically applied recombinant protein sold as a cosmetic ingredient falls outside its testing programme.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that bear on topically or intradermally delivered growth-factor preparations for hair loss, with the caveat that most of the primary trials they pool were run by the clinics and manufacturers that sell these treatments, a direct financial interest in a positive result that is named again in the Conclusion.

The trade-off is only partly represented. The claimed effect and the forgone benefit both have systematic reviews; the principal direct risk of this specific molecule, mast-cell and pigment-cell activation, has none, because no systematic review has examined recombinant stem cell factor applied to skin.

Mechanism of Action

sh-Polypeptide-4 is a bacterially produced copy of human stem cell factor, the only known ligand for KIT (a cell-surface receptor whose activation, through an attached enzyme, switches on growth and survival programmes). Binding pairs two KIT molecules, which phosphorylate each other and fire the MAPK/ERK cascade (a relay of enzymes carrying growth signals to the nucleus) and the PI3K-AKT pathway (a parallel survival and metabolism relay). Downstream, these raise MITF (the master control gene of pigment cells) and tyrosinase (the rate-limiting enzyme of melanin production). Inside the follicle the KIT-bearing cells are the pigment cells of the hair bulb and a reserve population of melanocyte precursors in the outer root sheath.

Key pharmacological properties: selectivity is essentially absolute, since KIT is its sole receptor; distribution is confined to KIT-bearing tissue (pigment cells, mast cells, blood-forming stem cells, germ cells, gut pacemaker cells); at roughly 18.5 kilodaltons (kDa, a unit of molecular mass) it is far above the ~500 Da ceiling for passive entry through intact skin; and it is disposed of by receptor-mediated uptake and ordinary protein breakdown, not by cytochrome P450 (CYP) liver enzymes. No published study reports a half-life for it in scalp tissue or after topical use.

Two readings compete. One holds that restoring the signal reactivates the follicle. The other notes that the membrane-anchored, not the soluble, form drives follicular pigmentation, so a soluble protein sitting on the skin surface may reproduce neither.

Historical Context & Evolution

Stem cell factor was identified around 1990 through two long-studied mouse mutants, Steel and White-spotting, whose defects in blood formation, pigmentation and fertility turned out to be the two halves of one signalling pair: the White-spotting locus encodes the KIT receptor and the Steel locus its ligand. The original intended use was therefore haematological. A recombinant version was developed through the 1990s to mobilise blood-forming stem cells into the circulation before transplantation, given together with a colony-stimulating factor. It was licensed in only a few countries and never achieved wide adoption, largely because injecting it provoked mast-cell reactions severe enough to require routine antihistamine premedication.

Its move toward hair came from follicle biology rather than from that clinical programme. Work at Bradford mapping KIT-positive cells through the human follicle found that pigment-cell numbers and receptor expression were unchanged in balding follicles, but that cultured dermal papilla cells from balding scalp secreted less stem cell factor than cells from unaffected scalp. That is a specific, still-standing observation about hair colour rather than hair size, and it has not been retracted or contradicted.

What changed afterwards was commercial rather than scientific. Recombinant growth factors entered cosmetic manufacturing under standardised ingredient names, and sh-Polypeptide-4 was folded into multi-factor scalp serums marketed for regrowth, an inference that reaches beyond what the pigmentation finding established in either direction.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the class of evidence that would qualify, a hair-count, hair-caliber or investigator-rated clinical endpoint replicated across more than one controlled trial of sh-Polypeptide-4, does not exist, because no controlled trial of the isolated molecule has been published.

Medium 🟩 🟩

No benefit reaches Medium either: not even a single controlled trial or consistent observational series measures a clinical hair endpoint for sh-Polypeptide-4 alone; every human dataset comes from multi-ingredient preparations in which its individual contribution cannot be separated.

Low 🟩

Increased Hair Density and Shaft Caliber Within Multi-Factor Preparations

Stem cell factor is one of many proteins in stem-cell conditioned media and growth-factor concentrates applied to or injected into the scalp. Pooled human trials of those mixtures show higher hair counts and thicker shafts, but no arm isolates sh-Polypeptide-4, and the trials carry high risk of bias.

Magnitude: Pooled gain of 14.93 hairs/cm² (95% confidence interval 10.20-19.67, the range in which the true effect most likely lies) across eight conditioned-media trials, and 57.1 hairs/cm² at 12 months for injected growth-factor concentrate; neither figure is attributable to sh-Polypeptide-4 alone.

Speculative 🟨

Maintenance of Hair-Shaft Pigmentation

Stem cell factor drives the KIT pathway that hair-bulb pigment cells use to make melanin. Supporting work is mouse pelage and human follicle organ culture; no human outcome data exist; the basis is mechanistic only.

Replacement of the Dermal Papilla Signal Deficit in Pattern Hair Loss

Cells at the base of balding follicles secrete less stem cell factor than unaffected cells, the stated rationale for putting it back. No human study has tested replacement; the basis is mechanistic inference.

Benefit-Modifying Factors

  • KITLG and KIT variants: KITLG (the gene encoding stem cell factor) and KIT (its receptor gene) carry common pigmentation-associated variants. Anyone whose receptor signalling is already saturated or already impaired would be expected to respond differently, though no study has stratified by genotype.

  • MC1R status: MC1R (the gene setting the switch between red-yellow and brown-black pigment) sits downstream of the same control network. Red-haired variants blunt the melanin output this molecule is supposed to raise, limiting any colour-related benefit.

  • Baseline miniaturisation and follicle reserve: Benefit tracks how much living follicle remains. Regions whose ratio of thick terminal hairs to fine vellus hairs stays above roughly 2:1 retain regrowable follicles; fully fibrosed regions offer no target.

  • Baseline nutritional biomarkers: Low ferritin (the storage form of iron), low vitamin D or untreated thyroid disease independently suppress the hair growth phase. Correcting them raises the ceiling on what any topical can add.

  • Sex: No sex-specific data exist for this molecule. Indirectly, pattern hair loss in women is more often diffuse with more surviving follicles, which plausibly leaves more responsive tissue than an advanced male vertex.

  • Pre-existing scalp inflammation: Untreated seborrhoeic dermatitis or lichen planopilaris (an inflammatory scarring hair loss) both destroy or suppress follicles faster than any growth signal can act, and inflamed skin also changes how much protein penetrates.

  • Age: Older follicles cycle with a shorter growth phase and a depleted pigment-cell reserve. Toward the upper end of the target range, the pigment-related mechanism has progressively less substrate to work with.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the qualifying class of evidence, a documented adverse event recorded in more than one controlled human trial of sh-Polypeptide-4, does not exist, because no controlled trial of the topical form has been published.

Medium 🟥 🟥

Mast-Cell Activation and Urticarial Skin Reactions

Stem cell factor is the survival and activation signal for mast cells (immune cells in skin that release histamine). In the phase I trial of the recombinant protein given by injection, every injection site raised a hive-like wheal-and-flare reaction, dermal mast cells showed anaphylactic-type degranulation, and mast-cell density rose even at untreated sites. Dosing was parenteral and far above anything a cosmetic serum delivers through intact skin, so the topical risk is plausibly much lower but has never been measured.

Magnitude: A wheal-and-flare reaction at every injection site in all 10 patients dosed at 5-50 µg/kg/day, with measurable rises in serum alpha-tryptase (a blood marker of mast-cell activation) and urinary methyl-histamine (a breakdown product of histamine). No figure exists for topical application.

Persistent Skin Hyperpigmentation at Application Sites

The same receptor pathway expands and activates pigment cells, so treated skin can darken rather than just the hair. In that trial, half the patients developed lasting darkening at injection sites, with biopsy showing increased epidermal melanin and more pigment cells. Because scalp serums are spread over wide areas and often applied onto needled skin, patchy darkening of exposed scalp is the plausible topical analogue, though no trial has looked for it.

Magnitude: Persistent hyperpigmentation at injection sites in 5 of 10 patients (50%) after a 14-day parenteral course; no incidence figure exists for topical or scalp use.

Low 🟥

Application-Site Irritation and Contact Sensitisation

These serums are usually driven in with microneedling, fractional laser or intradermal injection, and a systematic review of mesotherapy for hair loss records local adverse effects across agents delivered this way. Reports are uncontrolled and do not separate the protein from the vehicle, the preservative or the needling.

Magnitude: Not quantified in available studies. The mesotherapy literature reports adverse effects narratively rather than as pooled incidence, and no controlled trial of a sh-Polypeptide-4 serum has collected tolerability data at all.

Forgone Benefit From Substituting for Established Therapy

Pattern hair loss keeps progressing while an unproven product is used, and follicles that fully regress cannot be recovered. Pooled trials of topical minoxidil show a clear advantage over placebo, so replacing rather than adding a growth-factor serum forfeits a documented gain in exchange for an untested one.

Magnitude: Topical minoxidil beat placebo by a mean difference of 16.68 in percent increase in hair count from baseline (95% confidence interval 9.34-24.03); each year spent substituting for it forfeits a share of that recoverable density.

Speculative 🟨

Proliferative Signalling in Pigment and Mast Cells

KIT is a proto-oncogene (a normal gene that drives tumour growth when locked on), and its ligand expands pigment-cell and mast-cell populations. Whether repeated scalp exposure matters is untested; the concern is mechanistic.

Immune Response Against the Body’s Own Stem Cell Factor

Repeated exposure to a bacterially produced human protein can in principle raise antibodies that cross-react with the body’s own version. No topical study has measured this, so the risk remains theoretical.

Risk-Modifying Factors

  • KIT gain-of-function variants: The KIT D816V mutation (which locks the receptor permanently on) underlies most systemic mastocytosis (a disorder of overgrown, overactive mast cells). Adding ligand to already-autonomous mast cells is the worst case for the urticarial risk above.

  • Baseline serum tryptase: A resting tryptase above roughly 8 ng/mL flags an expanded mast-cell burden and identifies the people most likely to react badly to a mast-cell growth signal applied to skin.

  • Sex: No sex-specific adverse-event data exist for this protein. Women are diagnosed with chronic spontaneous urticaria more often, which indirectly suggests a larger reactive mast-cell population on average.

  • Pre-existing mast-cell and pigment conditions: Mastocytosis, urticaria pigmentosa (brown patches of clustered skin mast cells), chronic urticaria, melasma (patchy facial darkening), a history of melanoma or dysplastic naevus syndrome (many atypical moles) all sit directly downstream of KIT signalling.

  • Age: Older scalp skin has a thinner barrier and more actinic damage (accumulated sun damage), so more protein enters and it enters pigment-cell populations already carrying more mutations. Age also raises baseline melanoma risk.

Key Interactions & Contraindications

  • KIT-inhibiting drugs (imatinib, sunitinib, ripretinib): Direct pharmacological antagonism at the same receptor. Severity: expect loss of effect, not harm. Anyone taking these for a KIT-driven tumour has no plausible benefit to gain from applying the ligand.

  • Systemic and potent topical corticosteroids (prednisone, dexamethasone, clobetasol): Suppress mast-cell mediator release and blunt the local reaction. Severity: caution. Their use can mask an emerging urticarial response, delaying recognition; separating scalp application sites is the practical mitigation.

  • Oral antihistamines (cetirizine, fexofenadine, over the counter): Reduce the wheal-and-flare response without stopping mast-cell expansion. Severity: caution. They were used as premedication in the parenteral programme; taken casually, they hide the main early warning sign.

  • Topical minoxidil: No known chemical interaction; effects on the follicle are through different pathways. Severity: monitor only. Applying both wet products together dilutes each; protocols separate them by at least 30 minutes.

  • Topical retinoids (tretinoin, adapalene), salicylic acid and alcohol-based vehicles: All disrupt the barrier and increase how much protein reaches living skin. Severity: caution. Additive irritation and unpredictably higher exposure; stagger by at least 12 hours rather than layering.

  • Microneedling, fractional laser and mesotherapy: These are the delivery methods, not incidental co-treatments, and they convert a cosmetic surface application into intradermal dosing. Severity: caution. Consequence is the full mast-cell and pigment response described above.

  • Platelet-rich plasma (PRP) and exosome preparations: PRP is a concentrate of the patient’s own platelets, itself rich in growth factors. Severity: monitor. Additive growth-factor load with no dosing data; combining them makes attribution of any effect or reaction impossible.

  • Copper peptide (GHK-Cu) and other cosmetic peptide actives: Additive stimulation of dermal signalling. Severity: monitor. Copper ions can also degrade recombinant proteins in a shared formulation, so combined products may deliver less than they claim.

Populations who should avoid sh-Polypeptide-4:

  • Systemic or cutaneous mastocytosis of any subtype, or a baseline serum tryptase above 20 ng/mL
  • Documented KIT D816V mutation, or current or prior gastrointestinal stromal tumour (GIST, a KIT-driven tumour of the gut wall)
  • Personal history of melanoma, or dysplastic naevus syndrome with five or more atypical moles on the scalp or neck
  • Prior anaphylaxis or chronic spontaneous urticaria requiring more than standard-dose antihistamines
  • Active scalp infection, erosive scalp dermatitis, or scarring alopecia in the active inflammatory phase
  • Pregnancy and lactation, where no exposure data of any kind exist

Risk Mitigation Strategies

  • Patch test before scalp-wide use: Protocols confine the first 7 days to a 2 cm area behind the ear, inspected at 20 minutes and 24 hours. This detects the urticarial reaction before the whole scalp is exposed.

  • Baseline tryptase in anyone with a mast-cell history: Serum tryptase is measured before the first application where flushing, chronic hives or unexplained anaphylaxis has occurred, identifying the expanded mast-cell burden that makes a mast-cell growth signal a poor choice.

  • Separate application from barrier disruption: Protocols leave at least 24 hours between microneedling or fractional laser and the next serum application, limiting the uncontrolled intradermal dose that drives both the urticarial and the pigment responses.

  • Fixed-lighting scalp photography every 4 weeks: Standardised part-line and vertex images at the same distance and exposure. Catches patchy hyperpigmentation of scalp skin early, while it is still reversible on withdrawal.

  • Retention of an established therapy: Protocols position the serum as an addition to, not a replacement for, whatever proven topical or oral therapy is already working. This directly mitigates the forgone-benefit risk of substituting an untested product.

  • Discontinuation at the first urticarial sign: Protocols call for discontinuation at the first urticarial sign rather than dose reduction, because mast-cell expansion continues while exposure continues and reactions at untreated sites signal a systemic mast-cell response.

Therapeutic Protocol

  • No validated protocol exists: No clinic or trial has published a dosing schedule for sh-Polypeptide-4 as a single agent. Everything below reflects how multi-factor growth-factor serums are actually used, not a regimen with an efficacy trial behind it.

  • Conventional approach: Twice-daily topical application of a multi-factor serum to a dry scalp, 1-2 mL per session, continued for at least two full hair cycles (6-12 months) before any judgement of response.

  • Procedural approach: Growth-factor serum applied after microneedling at 0.5-1.5 mm or fractional laser, in 3-6 sessions spaced 2-6 weeks apart, a schedule covered by a systematic review of microneedling, as used in the growth-factor cocktail trial by Quirino and Rocha.

  • Neither is the default: The topical route has no efficacy evidence but negligible risk; the procedural route has weak efficacy evidence and carries the intradermal risks. The choice is between different unknowns, not between an established and an alternative option.

  • Popularised by: Aesthetic dermatology and hair-restoration clinics rather than any single investigator; the laser-plus-growth-factor variant is under formal study at University Medical Center Hamburg-Eppendorf.

  • Time of day: Applied to a clean, dry scalp morning and evening. No circadian data exist for this protein; evening application simply avoids sweat and daytime washing-off.

  • Half-life and dose splitting: No half-life has been published for the protein in scalp tissue. Receptor-mediated clearance is rapid, which is the stated rationale for split twice-daily dosing rather than a single larger application.

  • Genetic considerations: No pharmacogenetic testing informs dosing. KIT D816V status, where already known, is a reason not to use it at all rather than a dose modifier.

  • Sex-based differences: No sex-specific dosing exists. Protocols in women more often target diffuse mid-scalp thinning across a wider area, which raises the applied volume rather than the concentration.

  • Age-related considerations: Older scalp skin absorbs more and repairs more slowly, so protocols at the upper end of the target range space procedural sessions further apart, typically 6 weeks rather than 2-4.

  • Baseline biomarkers: Ferritin, vitamin D and thyroid function are corrected first in most protocols, since a deficiency-driven growth-phase shortening will otherwise mask any topical effect.

  • Pre-existing conditions: Active seborrhoeic dermatitis is treated to quiescence before starting, both because inflammation suppresses the follicle and because inflamed skin gives an unpredictable delivered dose.

Discontinuation & Cycling

  • Duration: Framed as indefinite. Any effect would depend on continuous receptor stimulation, so the intervention behaves like the other topicals for pattern hair loss rather than like a course of treatment.

  • Withdrawal effects: None documented. The parenteral programme reported no withdrawal syndrome, and mast-cell and pigment changes at treated sites resolved over weeks to months once dosing stopped.

  • Tapering: No taper protocol exists or is mechanistically indicated. Abrupt discontinuation is what was done in the clinical programme and what the cosmetic route implies.

  • Post-discontinuation shedding: Any hair maintained in the growth phase by continued signalling would be expected to shed within 3-4 months of stopping, mirroring what happens with other topical agents.

  • Cycling: Not established either way. No study has compared continuous with intermittent use; the theoretical case for pausing rests on limiting cumulative mast-cell expansion, not on preserving efficacy.

Sourcing and Quality

  • Expression system and purity: Produced by fermentation in Escherichia coli, so the protein is non-glycosylated and carries bacterial endotoxin risk. The relevant markers are a stated endotoxin limit and purity above 95% by chromatographic assay on the certificate of analysis.

  • Disclosed concentration: Most serums list sh-Polypeptide-4 near the end of the ingredient list without a figure. Products stating micrograms per millilitre are the informative exception; an ingredient present at a cosmetic trace level cannot deliver a biological dose.

  • Third-party testing: No independent testing programme covers cosmetic growth factors, so no verification body exists to consult. The practical substitute is a batch-specific certificate of analysis from an accredited contract laboratory, with identity confirmed by mass spectrometry.

  • Formulation stability: Recombinant proteins denature in water at room temperature. Two-part lyophilised powder-plus-activator kits, or refrigerated single-use ampoules, preserve activity; a shelf-stable clear serum in a pump bottle likely does not.

  • Ingredient-name conflation: sh-Polypeptide-4 is stem cell factor; sh-Polypeptide-1 is basic fibroblast growth factor and sh-Oligopeptide-2 is insulin-like growth factor 1. Marketing frequently treats “growth factor complex” as interchangeable with a specific molecule.

  • Compounding pharmacies: Not a realistic route. Recombinant proteins are not standard compounding stock, and a compounded preparation for hair regrowth would be an unapproved drug rather than a cosmetic.

Practical Considerations

  • Time to effect: No effect has been demonstrated, so no time course exists. If the growth-factor class is used as a guide, density changes in those trials appeared between 3 and 6 months, and 12 months is the usual full assessment point.

  • Regulatory status: Marketed as a cosmetic ingredient, not an approved drug. The U.S. Food and Drug Administration (FDA) has approved no growth factor for hair regrowth; any product making a regrowth claim is, by that claim, an unapproved drug.

  • Who funds the evidence: Almost all supporting data come from ingredient suppliers, cosmetic manufacturers and clinics selling the procedure. No professional-society guideline endorses this ingredient, so no organisation’s revenue position is being adopted here as evidence.

  • No payer incentive either way: Pattern hair loss is treated as cosmetic by insurers and national health systems, so treatment is self-funded almost everywhere. Structural bias therefore runs through manufacturers and clinics, not through institutional payers.

  • Cost and accessibility: Growth-factor serums typically run 10-40 times the monthly cost of generic minoxidil, and clinic-delivered protocols add per-session fees. Availability is unrestricted online, with no prescription and no potency standard.

  • Common pitfalls: Expecting a surface-applied 18.5 kDa protein to cross intact skin; buying a multi-factor blend and attributing any change to this one ingredient; and stopping at 3 months, before a single hair cycle has completed.

Interaction with Foundational Habits

  • Sleep: No direct interaction; the protein has no known circadian or sedative activity and is not systemically absorbed in meaningful amounts. Indirectly, chronic short sleep raises cortisol, and cortisol signalling holds hair-follicle stem cells quiescent, working against any growth signal applied topically.

  • Nutrition: Indirect and permissive. Iron, vitamin D, zinc and total protein intake set the ceiling on growth-phase length, so deficiency blunts any added signal. No food interacts with the molecule itself; correcting low ferritin before starting is the practical step.

  • Exercise: Indirect and mildly potentiating through scalp perfusion, but with a practical conflict. Sweat and post-workout washing strip a topical serum, so applying it after rather than before training preserves contact time; no evidence links exercise to KIT signalling.

  • Stress management: Indirect and potentiating when addressed. Sustained glucocorticoid signalling suppresses the follicle stem-cell activation that any growth factor depends on, and stress-triggered telogen effluvium (diffuse shedding weeks after a stressor) can be mistaken for treatment failure.

Monitoring Protocol & Defining Success

Before starting, the useful baseline is mostly photographic rather than biochemical: standardised part-line, vertex and frontal images under fixed lighting, plus a trichoscopic count of total and terminal hairs in a marked 1 cm² target area, since no blood marker tracks response to this molecule. Alongside that, the correctable drivers of shedding are measured once, because an uncorrected deficiency will mask or mimic any effect, and serum tryptase is added only where a mast-cell history exists. Ongoing monitoring is scheduled at 3 months, 6 months and 12 months, with the deficiency panel repeated at 6 months if it was abnormal at baseline and annually thereafter; scalp photographs are repeated every 4 weeks during the first 3 months to catch pigmentation changes early. Success is defined as a measurable rise in terminal hair count in the marked area at 6 months, not as a subjective impression.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70-100 ng/mL (women); 100-150 ng/mL (men) Iron stores set growth-phase length Conventional labs flag deficiency only below 15-30 ng/mL, far under the hair threshold; ferritin rises with inflammation, so pair with C-reactive protein (CRP, a general inflammation marker)
25-hydroxyvitamin D 40-60 ng/mL Vitamin D receptor activity is required for follicle cycling Conventional sufficiency starts at 30 ng/mL; no fasting needed; recheck 3 months after any dose change
TSH 0.5-2.0 mIU/L Thyroid dysfunction causes diffuse shedding that mimics treatment failure TSH is thyroid-stimulating hormone; conventional range extends to 4.5 mIU/L; draw in the morning and pair with free T4 (free thyroxine, the active circulating thyroid hormone)
Serum total tryptase Below 8 ng/mL Flags the expanded mast-cell population most likely to react to a mast-cell growth signal Only indicated with a flushing, hives or anaphylaxis history; must be drawn at baseline, not within 24 hours of a reaction
Serum zinc 90-120 µg/dL Zinc deficiency shortens the growth phase and thins the shaft Conventional range starts near 60 µg/dL; draw fasting and avoid supplementing for 24 hours beforehand
Terminal-to-vellus hair ratio (1 cm² target area) At or above 4:1 Distinguishes recoverable thinning from follicles already lost Measured by trichoscopy, not blood; below 2:1 indicates advanced miniaturisation with little remaining target tissue
Total hair density (1 cm² target area) No established target exists for this intervention; track the change from the individual’s own baseline, with a gain of 10 or more hairs/cm² being the usual trial-level threshold The only direct measure of whether anything is working Same marked area, same device, same magnification each time; measure before washing, on dry hair, at the same time of day

Qualitative markers worth tracking alongside the numbers:

  • Shedding volume on the pillow and in the shower drain, counted the same way each week
  • Whether the scalp shows through under overhead lighting in the standardised photographs
  • Perceived shaft stiffness and body, which shifts before hair count does
  • Scalp comfort: itch, tightness, flushing or warmth after application
  • Any new or darkening patches of scalp skin, examined monthly

Emerging Research

  • Peptide serum against minoxidil head-to-head (NCT07536100): A randomised, triple-masked 80-participant trial at the Institute of Dermatology, Thailand, comparing a peptide-factor hair serum with 2% minoxidil over 24 weeks, with hair density as the primary endpoint. The manufacturer is a named collaborator.

  • Laser-assisted growth-factor delivery (NCT07079657): A 30-participant randomised trial at University Medical Center Hamburg-Eppendorf testing thulium laser alone against laser plus growth-factor serum, with or without light therapy, over three sessions six weeks apart. It isolates the contribution of the serum from the device.

  • Cell-free growth-factor payloads (NCT06697080): A 50-participant randomised trial at Nanfang Hospital comparing dosing frequencies of umbilical cord mesenchymal stem cell exosomes, tracking hair diameter and density to 6 months. Relevant because such payloads carry the same signalling proteins.

  • No trial of the isolated molecule: A ClinicalTrials.gov search for stem cell factor in alopecia returns nothing. Until one registers, every human figure quoted for sh-Polypeptide-4 will remain borrowed from mixtures.

  • Evidence that could weaken the case: Randall et al., 2008 found pigment-cell numbers and KIT expression unchanged in balding follicles, locating the deficit in pigment production rather than follicle size. Confirmation would place this molecule in hair colour, not regrowth.

  • Evidence that could strengthen it: Hachiya et al., 2009 showed receptor blockade reversibly depigments human follicles in organ culture. A delivery system proving the same axis is reachable through scalp skin would convert the mechanism into a testable claim.

  • Delivery is the rate-limiting question: Whether an 18.5 kDa protein reaches the follicle at all is unresolved, and the systematic review of microneedling in hair loss is the closest thing to a controlled test of the delivery step itself.

Conclusion

sh-Polypeptide-4 is a manufactured copy of a natural signalling protein, sold in scalp serums on the strength of a real but narrow biological finding: cells at the base of thinning follicles release less of this protein than healthy ones, and the protein is needed for the pigment cells that colour a growing hair. That finding concerns hair colour more than hair thickness, and the leap from it to regrowth has not been made in any study of the ingredient by itself.

What human evidence exists comes from mixtures containing many such proteins, where nothing separates out the contribution of this one, and from a small hospital study in which the same protein was injected rather than applied. That study is also the source of the clearest safety signal: raised hives where the protein went in, and lasting skin darkening in many of those treated, at doses far higher than a serum could deliver through unbroken skin.

Two further limits matter. The molecule is large enough that intact skin should block it, so any real effect probably depends on breaking the barrier first. And nearly all the supporting material comes from the companies and clinics that sell these products, which is a direct financial stake in a favourable answer. For anyone weighing this against treatments with measured results, the gap is between a plausible idea and an untested one.

Top - Benefits - Risks - Protocol